Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab Long-Term Safety in Atopic Dermatitis
NCT04086121Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2019
- Primary completion
- Apr 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of spesolimab in atopic dermatitis (AD), sponsored by Boehringer Ingelheim. Started Sep 2019; status: terminated.
02
Drugs
spesolimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04086121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04086121.